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Summary
CARMA1mediates T cell receptor (TCR)-induced NF-kB
activation. However, how TCR links to CARMA1 in the
signaling pathway is not clear. Here, we show that
CARMA1 is inducibly phosphorylated after TCR-CD28
costimulation. This phosphorylation is likely induced
by PKCq, since PKCq induces phosphorylation of
CARMA1 in vitro and in vivo. Our results indicate that
the PKCq-induced phosphorylation of CARMA1 likely
occurs on Ser552 on the Linker region of CARMA1. Im-
portantly, expression of CARMA1 mutant, in which
Ser552 is mutated, fails to mediate TCR-induced NF-kB
activation in CARMA1-deficient T cells. The functional
defect of this CARMA1 mutant is likely due to the fact
that thismutant cannot bephosphorylated at the critical
residue, thereby failing to recruit the downstream sig-
naling components into the immunological synapse.
Together, our studies provide the first genetic evidence
that thephosphorylationofCARMA1plays acritical role
in the TCR signaling pathway.
Introduction
Activation of T cells plays a central role in regulation of
immune responses. This process is induced by MHC
molecules on antigen-presenting cells (APC) presenting
antigen peptides to T cell receptors (TCR) on the surface
of T cells. The stimulation on TCR and CD3 complexes
induces a series of signaling transduction events lead-
ing to activation of cytosolic tyrosine kinases such as
Lck, ZAP70, Lyn, and Fyn, which, in turn, phosphorylate
various adaptor proteins including LAT, SLP76, Vav, and
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recruit effector proteins, such as small GTPases, serine/
threonine kinases, and phospholipase C g1 (PLCg1),
leading to activation of multiple transcription factors in-
cluding NF-AT, NF-kB, and AP-1 (Clements et al., 1999).
These activated transcription factors regulate cytokine
production and cell proliferation. Stimulation of TCR/
CD3 complexes only induces a basal level of NF-kB ac-
tivation. Optimal activation of NF-kB requires a second
costimulatory signal through interactions between B7-
1(CD80)/B7-2(CD86) molecules on APCs and CD28 re-
ceptors on T cells. This combined stimulation of TCR/
CD3 complexes and CD28 receptors (known as ‘‘CD3-
CD28 costimulation’’) leads to the optimal activation of
NF-kB (Kane et al., 2002).
NF-kB plays a critical role in regulating T cell activation
by inducing the expression of various genes that control
T cell activation, proliferation, and survival (Ghosh et al.,
1998). NF-kB is a family of transcription factors that con-
tains Rel homology DNA binding domains and exists as
various homo- or heterodimers. In unstimulated cells,
NF-kB is sequestered in the cytoplasm by a family of in-
hibitory proteins, IkB, which masks the nuclear localiza-
tion domain of NF-kB subunits (Baldwin, 1996). Treat-
ment of cells with various stimuli, such as TNFa, IL-1b,
PMA, or CD3-CD28 costimulation, initiates signal trans-
duction cascades leading to activation of IkB kinase
(IKK). IKK phosphorylates the regulatory serine residues
located in the N terminus of IkB molecules, triggering
rapid ubiquitination and proteolysis of IkBs in the 26S
proteasome complex. The degradation of IkB molecules
unmasks the nuclear localization signal of p65 in the p50/
p65 heterodimeric NF-kB complexes, which rapidly
translocate into the nucleus and engage cognate kB en-
hancer elements and modulate the transcription of vari-
ous genes involved in inflammatory and immune re-
sponses (Karin and Ben-Neriah, 2000).
Although it is clear that CD3-CD28 costimulation acti-
vates NF-kB through activation of IKKs in T cells, the
molecular mechanism by which CD3-CD28 costimula-
tion leads to activation of IKK is not fully understood.
Previous studies indicate that CD3-CD28 costimulation
induces formation of a large, multicomponent complex
at the site of contact between T cell and APC, termed
the supramolecular activation complex (SMAC) or the
immunological synapse (IS) (Bromley et al., 2001). This
contact area of the T cell is highly enriched in cholesterol
and glycosphingolipids, also termed lipid rafts or micro-
domains (Xavier and Seed, 1999). Some signaling mole-
cules, including Lck, LAT, and Ras, are constitutively
associated with the lipid rafts, whereas other signaling
molecules, such as PKCq, PLCg1, ZAP70, Vav, SLP76,
and IKKb, are recruited into the lipid rafts after CD3-
CD28 costimulation (Xavier and Seed, 1999). Previous
studies indicate that CD3-CD28 costimulation leads to
activation of PLC-g1 through various adaptor molecules
(Clements et al., 1999). The activated PLCg1 hydrolyzes
inositol phospholipids (PIP2) into inositol triphosphates
(IP3) and diacylglycerols (DAG). The production of IP3
leads to an elevation of intracellular calcium levels
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intracellular calcium and DAG activate protein kinase C
(PKC).
PKC is a family of serine/threonine kinases. At pres-
ent, 11 different PKC isoforms have been identified
and grouped into three subclasses based on their ability
to respond to calcium (Ca2+) and/or diacylglycerols
(DAG). Both the classic PKCs (cPKCs), such as a, bI,
bII, and g, and the novel PKCs (nPKCs), such as d, 3, h,
and q, are activated by DAG or experimental analogs
like phorbol myristylacetate (PMA). However, the cPKCs
but not the nPKCs also respond to a change of intracel-
lular calcium levels. In contrast, atypical PKCs (aPKCs),
such as z and l/t, do not respond to either Ca2+ or PMA.
Previous studies indicate that PKCq is the major isoform
of PKC moving into the immunological synapse (Monks
et al., 1997) and mediating the NF-kB activation after
CD3-CD28 costimulation (Coudronniere et al., 2000;
Lin et al., 2000; Sun et al., 2000). However, the mecha-
nism by which PKCq leads to activation of IKKb remains
to be determined.
Recent studies have demonstrated that a newly
identified membrane-associated guanylate-kinase-like
(MAGUK) molecule, CARMA1, is required for CD3-
CD28 costimulation-induced NF-kB activation and func-
tions downstream of PKCq (Egawa et al., 2003; Hara
et al., 2003; Jun et al., 2003; Newton and Dixit, 2003;
Wang et al., 2002). CARMA1 contains an N-terminal
caspase-recruitment domain (CARD) following with a
coiled-coil domain (C-C), a PDZ domain, a SH3 domain,
and guanylate kinase (GUK)-like domain (Bertin et al.,
2001; Gaide et al., 2001). It has two mammalian homo-
logs, CARMA2 and CARMA3 (Bertin et al., 2001; Gaide
et al., 2001; McAllister-Lucas et al., 2001; Wang et al.,
2001). These three CARMA proteins exhibit a distinct tis-
sue distribution pattern. Specifically, CARMA1 is pre-
dominantly expressed in spleen, thymus, and peripheral
blood leukocyte (PBL); CARMA2 is expressed only in
placenta; and CARMA3 is expressed in broad range of
tissues but not in spleen, thymus, or PBL. After CD3-
CD28 costimulation, CARMA1 associates with Bcl10-
MALT1 complex and recruits these proteins into the lipid
rafts by an unknown mechanism (Che et al., 2004; Gaide
et al., 2002; Hara et al., 2004; Wang et al., 2004). The re-
cruitment of the Bcl10-MALT1 complex has been shown
to activate IKK through a ubiquitin-dependent pathway
(Sun et al., 2004; Zhou et al., 2004) after CD3-CD28 cos-
timulation, leading to activation of NF-kB (Ruefli-Brasse
et al., 2003; Ruland et al., 2001, 2003; Xue et al., 2003).
However, the mechanism by which PKCq links to
CARMA1 and leads to recruitment of the Bcl1-MALT1
complex remains to be determined.
In this study, we found that CARMA1 is phosphory-
lated after TCR stimulation. This phosphorylation may
be induced by PKCs, such as PKCq, in T cells, since
PKCq is the major isoform of PKCs, which translocates
into the immunological synapse (Monks et al., 1997),
and mediates TCR-induced NF-kB activation (Sun
et al., 2000). Our mutagenesis studies indicate that
Ser552 in the Linker region of CARMA1 is one of the crit-
ical sites for PKC-dependent phosphorylation. Impor-
tantly, expression of a CARMA1 mutant with mutation
on this Ser residue failed to rescue TCR-induced
NF-kB activation in CARMA1-deficient cells. Together,these results provide genetic evidence that the phos-
phorylation of CARMA1 plays a critical role in TCR signal
transduction.
Results
Previous studies indicate that Bcl10 is a signaling com-
ponent downstream of PKCs in antigen-receptor signal-
ing pathways (Ruland et al., 2001; Xue et al., 2003). Since
Bcl10 contains a Ser/Thr-rich C-terminal domain, we ini-
tially decided to determine whether Bcl10 is phosphory-
lated after activation of PKCs in T cells. To do this, we
first labeled Jurkat T cells with 32P-orthophosphate.
The labeled cells were stimulated with PMA, a pharma-
cological homolog of DAG that bypasses the proximal
TCR components and directly activates PKCs, plus
anti-CD28 antibodies that crosslink CD28 molecules
on T cell surfaces. This stimulation mimics the stimula-
tion of TCR and CD28 complexes. Bcl10 was immuno-
precipitated after the stimulation. Although there was
no significant induction of Bcl10 phosphorylation, we
found that an unknown 130 kDa protein coimmunopre-
cipitated with Bcl10 was inducibly phosphorylated after
the stimulation (Figure 1A). Since Bcl10 is inducibly as-
sociated with CARMA1 after TCR stimulation (Gaide
et al., 2002), and the molecular size of CARMA1 is about
130 kDa, we then postulated that the coimmunoprecipi-
tated phospho-protein might be CARMA1. However, we
were unable to confirm that this unknown phospho-
protein was CARMA1, due to the lower sensitivity of
anti-CARMA1 antibodies for detecting endogenous
CARMA1. To directly examine whether CARMA1 is in-
ducibly phosphorylated after TCR stimulation, we per-
formed a similar 32P-labeling experiment as for Bcl10-
labeling. Instead of the immunoprecipitation of Bcl10,
CARMA1 was directly immunoprecipitated from the
cell lysates. We found that CARMA1 was indeed phos-
phorylated, and this phosphorylation was slightly
increased after PMA-CD28 costimulation (Figure 1B).
Together, these results suggest that CARMA1 is consti-
tutively phosphorylated, and TCR signaling pathway
further induces phosphorylation of CARMA1.
Since PKCq has been shown to mediate TCR-induced
NF-kB activation and functions upstream of CARMA1
(Wang et al., 2002), we next determined whether PKCq
could induce phosphorylation of CARMA1. The expres-
sion vector of CARMA1 was cotransfected with the wild-
type (wt) or a constitutively active (AE) version of PKCq
to HEK293 cells. PKCq-induced phosphorylation of
CARMA1 was examined by 32P-orthophosphate-
labeling experiments. We found that the expression of
PKCq(AE) potently induced phosphorylation of CARMA1
(Figure 2A). This result further confirms that PKCq func-
tions upstream of CARMA1. Since we recently found
that PKCq associated with CARMA1 (Wang et al.,
2004), we then examined whether CARMA1 is a sub-
strate of PKCq. Due to the technical difficulties of ob-
taining recombinant full-length CARMA1 proteins, we
expressed Flag-tagged CARMA1 in HEK293 cells and
purified the Flag-tagged CARMA1 by immunoprecipita-
tion from the transfected cells. To determine whether
PKCq phosphorylates CARMA1, we used recombinant
PKCq to phosphorylate the immunoprecipitated
CARMA1 in an in vitro kinase assay. As controls, we
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577Figure 1. CARMA1 Is Phosphorylated after
PMA-CD28 Costimulation
Jurkat T cells (1 3 107/sample) were cultured
in phospho-free media for 1 hr, and then 32P-
orthophosphate was added into the culture
for 1 hr. The 32P-labeled cells were stimulated
with or without 10 ng/ml of PMA plus 1 mg/ml
of anti-CD28 antibodies for various time
points. The cells were washed once with
PBS and lysed in 200 ml of lysis buffer after
the stimulation. Endogenous Bcl10 and
CARMA1 proteins were immunoprecipitated
from the cell lysates by anti-Bcl10 (A) or anti-
CARMA1 (B) antibody-conjugated agarose
beads. The immunoprecipitates were sub-
jected to SDS-PAGE and then transferred to
Nylon membranes and analyzed by autoradi-
ography and immunoblotting.also used the immunoprecipitated Bcl10 and MALT1 as
substrates in this kinase assay. We found that PKCq se-
lectively phosphorylated CARMA1, but not Bcl10 and
MALT1, in vitro (Figure 2B). Together, these results sug-
gest that PKCq phosphorylates CARMA1.
Our recent studies suggest that PKCq associates with
the Linker region (residues 432–671) (Figures 3A and 3B)
between the coiled-coil and PDZ domains of CARMA1
(Wang et al., 2004), and 32P-labeling results suggest
that PKCq can phosphorylate the Linker region (data
not shown). Therefore, we hypothesized that PKCq
might regulate CARMA1’s function through phosphory-
lating the Linker region. Based on the prediction from
the PKC substrate-prediction program in Scansite
(http://scansite.mit.edu), we found that the Linker region
of CARMA1 contains several Ser residues that are po-
tential phosphorylation sites for classical (a and b) or
novel (d, 3, or h) PKCs. In addition, CARMA1 has two ho-
mologs, CARMA2 and CARMA3, that contain similar
structural domains to CARMA1 (Figure 3A) but are ex-
pressed in nonlymphoid tissues (Bertin et al., 2001;
Gaide et al., 2001; McAllister-Lucas et al., 2001; Wang
et al., 2001). Interestingly, expression of CARMA3, but
not CARMA2, could effectively rescue TCR- or PMA-
induced NF-kB activation in CARMA1-deficient Jurkat
T cells (Figure 3C). These results suggest that CARMA3
contains some residues that are homologous to
CARMA1 and play important roles in TCR-induced NF-kB
activation. Therefore, we decided to focus our efforts
on the Ser residues that are conserved in CARMA1and CARMA3, but not in CARMA2, based on the se-
quence alignment (Figure 3B), and those Ser residues
that are potential PKC phosphorylation sites.
Based on these two criteria, we generated a series of
CARMA1 mutants (S505A, S508A, S549A, S551A,
S552A, S555A, S637A, S645A, S470/S471/S473A [3-SA],
S549/S551/S552A, S551/552A, S552/555A, and S611/
612/613/614/615A [5-SA]) in which single or multiple Ser
residues in the Linker region were changed to Ala. The
expression plasmids encoding wt or these mutants
of CARMA1 were transiently or stably transfected to
CARMA1-deficient T cells to examine their biological
functions. Expression of CARMA1(S555A) failed to rescue
PMA-CD28 costimulation-induced NF-kB activation,
whereas expression of CARMA1(S552A) or CARMA1
(S645A) could only rescue 30%–40% or 45%–50% of the
wt CARMA1’s activity, respectively (Figure 4A and Table
1). In contrast, other mutations with single or multiple
Ser residues on the Linker region of CARMA1 had no ef-
fects on the costimulation-induced NF-kB activation (Fig-
ure 4A and Table 1).
To further confirm the functional importance of Ser552
and Ser555 of CARMA1, we stably reconstituted
CARMA1-deficient Jurkat T cells with wt or mutants of
CARMA1 (Figure 4B, bottom). PMA-CD28 costimulation-
induced NF-kB activation in these cell lines was exam-
ined via electrophoretic mobility shift assay (EMSA).
Although all of reconstituted CARMA1 mutants were ex-
pressed in comparable levels (Figure 4B, lanes 5–10 in
the lower panels), only wt CARMA1 could effectively
Immunity
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CARMA1
(A) The expression vector of Flag-tagged
CARMA1 was cotransfected with or without
the expression vectors for wild-type or a con-
stitutively active (AE) version of PKCq into
HEK293 cells. The transfected cells were
labeled with 32P-orthophosphate. The cells
were washed once with PBS and lysed in
200 ml of lysis buffer after 1 hr of 32P-labeling.
Flag-tagged CARMA1 was immunoprecipi-
tated from the cell lysates by anti-Flag anti-
body-conjugated agarose beads.
(B) Flag- or Myc-tagged CARMA1, Bcl10, and
MALT1/M were immunoprecipitated with anti-
Flag antibody-conjugated agarose beads from
HEK293 cells that were transiently transfected
with their expression vectors. The immuno-
precipitated proteins were eluted from the
agarose beads by Flag or Myc peptides. The
eluted proteins were used as substrates for re-
combinant PKCq in the in vitro kinase assays.
The kinase reaction mixtures were subjected
to SDS-PAGE, transferred to Nylon mem-
branes, and analyzed by autoradiography and
immunoblotting.rescue CD3-CD28 or PMA-CD28 costimulation-induced
NF-kB activation (Figure 4B, lane 6 in the top panel) and
phosphorylation (Figure 4C, lanes 5 and 6) and degrada-
tion (data not shown) of IkBa. In contrast, both CAR-
MA1(S552) and CARMA1(S555A) failed to restore the
NF-kB activation (Figure 4B, lanes 8 and 10 in the top
panel) and the phosphorylation of IkBa (Figure 4C, lanes
8, 9, 11, and 12).
Since CARMA3, but not CARMA2, contains a Ser res-
idue (Ser520) in the homologous position of Ser552 or
555 in CARMA1 (Figure 3B), we decided to mutate
Ser520 of CARMA3 into Ala. Interestingly, the mutation
of Ser520 in CARMA3 also abolished its ability to rescue
TCR-induced NF-kB activation in CARMA1-deficient
T cells (see Figure S1 in the Supplemental Data available
with this article online). Of note, the Linker region of
CARMA1 and CARMA3 share only about 25% of homol-
ogy (Figure 3B), but the mutation of Ser520 in CARMA3
completely abolished its ability to rescue the CARMA1
defect, indicating that the homologous residues of
Ser552 and Ser555 in CARMA3 are very important
for its function. Together, these results indicate that
Ser552 and Ser555 of CARMA1 play a critical role in me-
diating TCR-induced NF-kB activation.
To examine whether PKCq directly phosphorylates
Ser552 and Ser555 of CARMA1, we performed an in vitro
kinase assay by recombinant PKCq (Figure 5A). Re-
combinant proteins that contain a glutathionine S-trans-
ferase (GST) domain fused to the Linker region (residue
432–671) of CARMA1 were generated. GST fusion pro-teins containing the Linker region with individual Ser res-
idue converted into Ala were also generated. These pro-
teins were used as substrates (Figure 5B, top) in the in
vitro kinase assay for the recombinant PKCq (Figure 5B,
bottom). Although the wild-type protein was effectively
phosphorylated by PKCq in the presence of PMA
(Figure 5A, lane 8), the PKCq-induced phosphorylation
of GST-fusion proteins containing the single mutation
of S552A was significantly reduced (Figure 5A, lane 9).
In contrast, individual mutation of S555A and S645A
and the combined mutations of S470A, S471A, and
S473A (3-SA) do not significantly affect PKCq-induced
phosphorylation (Figure 5A, lanes 10–12). In addition,
PKCq could not phosphorylate GST alone in the ab-
sence or presence of PMA (data not shown). Together,
our results suggest that Ser552 in the Linker region of
CARMA1 is one of the functional phosphorylation sites
for PKCq.
To further investigate whether Ser552 of CARMA1 is
phosphorylated after PMA/CD28 costimulation, we per-
formed the in vivo 32P-phospho-labeling experiments as
in Figure 1B via CARMA1-deficient cells reconstituted
with wt, S552A, or S555A version of CARMA1. However,
since the reconstituted CARMA1 proteins in CARMA1-
deficient cells were expressed in much higher levels
than the endogenous CARMA1 in normal Jurkat cells
(Figure S2), the reconstituted CARMA1 proteins were
constitutively phosphorylated at much higher levels
(Figure S2). Therefore, the signal-induced phosphor-
ylation of CARMA1 was unable to be detected in the
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(A) Structural domain of CARMA family members.
(B) Sequence aliments of the Linker region of CARMA1, CARMA2, and CARMA3. Ser552 and Ser555 are indicated in the shade area and arrows.
(C) JPM50.6 cells were transfected with vector encoding NF-kB-dependent luciferase (firefly) reporter and EF1a promoter-dependent Renilla
luciferase reporter together with or without expression vectors encoding Flag-CARMA1, Myc-CARMA2, and Flag-CARMA3. 18 hr after the trans-
fection, the transfected cells were stimulated with or without anti-CD3 and anti-CD28 antibodies or PMA (10 ng) plus anti-CD28 antibodies for
6 hr. The cells were lysed and luciferase activities in the cell lysates were measured by dual-luciferase kit. The Renilla luciferase activity was used
to normalize the transfection efficiency. All data are presented as the fold induction compared to nonstimulated vector controls. The standard
deviations were derived from values in three independent transfection samples. The lysates were also examined by Western blots by anti-Flag or
anti-Myc antibodies (the inserted gels). Lanes 1–4 are vector, Flag-CARMA1, Myc-CARMA2, and Flag-CARMA3.reconstituted cells (Figure S2). As the result, we were un-
able to use this in vivo 32P-labeling experiment to dem-
onstrate the in vivo phosphorylation of Ser552 in
CARMA1 (Figure S2).
To examine PKCq-induced phosphorylation of Ser552
in CARMA1, we also transfected plasmids encoding wt,
S552A, or S555A version of CARMA1 together with or
without the plasmid encoding PKCq(AE). CARMA1 pro-
teins were immunoprecipitated from the transfected
cells. The PKCq-induced phosphorylation of CARMA1
was examined with anti-PKC-phospho-substrates anti-
bodies, which could detect all potential phosphorylation
induced by PKC. Although we could easily detect PKCq-
induced phosphorylation, the mutations on Ser552 and
Ser555 have only small effects on PKC-induced phos-
phorylation in this overexpression experiment (Fig-
ure S3). This result suggests that PKCq could phosphor-
ylate multiple sites of CARMA1 when it is overexpressed.
Therefore, the mutation on Ser552 or Ser555 alone is not
sufficient to abolish the PKCq-induced phosphorylation
when it is overexpressed (Figure S3).
Finally, we performed in vivo peptide-mapping experi-
ments by using mass spectra. To do this, we stimulated
JPM50.6-Flag-tagged CARMA1(WT) cells with or with-
out PMA-CD28 for 5 min. The Flag-CARMA1(WT) pro-teins were immunoprecipitated, purified, digested with
trypsin, and analyzed with an LTQ LC/MS. Consistent
with the in vivo phospho-labeling results, we found
that multiple Ser/Thr residues were constitutively phos-
phorylated (data not shown). Although the majority of
the (551SSIMSITAEPPGNDSIVR568) peptide identified
was nonphosphorylated, a minor peptide peak that
matched to a phosphorylated peptide (551SS*IMSIT
AEPPGNDS*IVRRY*K571) was detected in the stimulated
sample (Figure S4A). The composition of this potential
phosphorylated peptide was further analyzed by frag-
mentation (Figure S4B). Several fragments in the MS
spectra matched to the phosphorylated peptide (Table
S1). Therefore, this result indicates the existence of the
peptide with phosphorylated Ser552 and Ser565. Al-
though Ser565 does not fall into a putative PKC phos-
phorylation site, we also generated S565A mutant of
CARMA1 and found that this mutant is also defective
for TCR-induced NF-kB activation (Table 1), which
further suggests the importance of this region for
CARMA1’s function.
Previous studies indicate that CARMA1 recruits down-
stream signaling components such as Bcl10, IKK, and
MALT1 into lipid rafts after CD3-CD28 costimulation
(Che et al., 2004; Gaide et al., 2002; Hara et al., 2004;
Immunity
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(A) JPM50.6 cells were transfected with vector encoding NF-kB-dependent luciferase (firefly) reporter and EF1a promoter-dependent Renilla
luciferase reporter with or without expression vectors encoding CARMA1 and its mutants. The transfected cells were stimulated and examined
as described in Figure 3C. The lysates were also examined by Western blots with anti-Flag antibodies (the inserted gel). Lanes 1–6 are vector, wt,
S552A, S555A, S552/555A, and 5-SA. The standard deviations were derived from values in three independent transfection samples.
(B) Jurkat cells or JPM50.6 cells that were reconstituted with or without PMA (10 ng) plus anti-CD28 antibodies for 1 hr. Nuclear extracts (10 mg)
from these cells were incubated with 32P-labeled probes containing NF-kB or Oct-1 binding sites for 15 min and then subjected to electropho-
resis in 5% polyacrylamide gel and autoradiography. Cytoplasm fractions from these cells were determined by Western blot (WB) by anti-Myc
and anti-Bcl10 antibodies.
(C) JPM50.6 cells that were reconstituted with or without lentiviral vectors encoded CARMA1, and its mutants were stimulated with anti-CD3 and
anti-CD28 antibodies for various times. IkBa or ERK phosphorylation was determined by Western blot (WB) with anti-p-IkBa, anti-p-ERK anti-
bodies. The membrane was then reprobed with anti-IkBa or ERK antibodies.Wang et al., 2004). Therefore, we hypothesized that the
phosphorylation of Ser552 of CARMA1 triggers a confor-
mational change in such a way that a binding site for
Table 1. Summary of CARMA1 Mutants and Their Functions
Mutants
Residues Mutated
to Ala
PMA-CD28
Costimulation-Induced
NF-kB Activation
3-SA Ser470, Ser471,
Ser473
>95%
S505A Ser505 >95%
S508A Ser508 >95%
S549A Ser549 >95%
S551A Ser551 >95%
S552A Ser552 30%–40%
S549/551/
552A
Ser549, Ser551,
Ser552
<5%
S551/552A Ser551, Ser552 30%–40%
S555A Ser555 <5%
S552/555A Ser552, Ser555 <5%
S565A Ser565 <10%
S637A Ser637 >95%
S645A Ser645 40%–50%
5-SA Ser611, Ser612,
Ser613, Ser614,
Ser615
>95%Bcl10 in CARMA1 is exposed, thereby recruiting down-
stream signaling components to lipid rafts. To test
this hypothesis, we determined whether mutations of
Ser552 and Ser555 in CARMA1 would affect the recruit-
ment of Bcl10 and NEMO to lipid rafts after CD3-CD28
costimulation. CARMA1-deficient cells reconstituted
with wt, S552A, or S555A version of CARMA1 (Figure 4B)
were stimulated with or without anti-CD3 and anti-CD28
antibodies (Figure 6A). The lipid rafts were prepared with
a sucrose-gradient centrifugation and examined by
SDS-PAGE and immunoblotting analyses. Consistent
with previous findings (Gaide et al., 2002; Hara et al.,
2004; Wang et al., 2004), Bcl10 and NEMO, the regulatory
subunit of IKK, were recruited into lipid rafts in the
cells expressing wild-type CARMA1 (Figure 6B, lane 2),
whereas the costimulation-induced recruitment of
Bcl10 and NEMO was defective in the cells expressing
CARMA1(S552A) or CARMA1(S555A) (Figure 6B, lanes
4 and 6). Therefore, the defect of the recruitment of
Bcl10 and NEMO resulted in the failure of CD3-CD28
costimulation-induced IkBa phosphorylation (Figure 4C)
and degradation (data not shown) and NF-kB activation
(Figure 4B). In contrast, the costimulation-induced ERK
activation was not defective (Figure 6A). To further inves-
tigate whether the observed defects of S552A and S555A
Phosphorylation of CARMA1 and NF-kB Activation
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Linker Region of CARMA1
Recombinant proteins containing GST alone
(lanes 1 and 7) or GST-wild-type or mutants
of the Linker region (residues 432–671) of
CARMA1 (lanes 2–6 and 8–12) were used as
substrates for PKCq in the absence or pres-
ence of PMA in the in vitro kinase assay.
Kinase reaction mixtures were subjected to
SDS-PAGE and transferred to Nylon mem-
branes and then analyzed by autoradiogra-
phy (A). The level of GST fusion proteins and
added PKCq were determined by Western
blots with anti-GST or anti-PKCq antibodies
(B).mutants are due to the defective recruitment of CARMA1
mutants to immunological synapse, we expressed GFP-
fused wt, S552A, S555A, and L808P versions of CARMA1
in Jurkat T cells. The lipid rafts of transfected cells were
labeled with red fluorescent ALEXA594-conjugated
cholera toxin B (CTx-ALEXA). The recruitment of GFP-
CARMA1 proteins to immunological synapses was ex-
amined by a confocal fluorescent microscope after the
conjugation of Staphylococcus exotoxin E (SEE)-primed
or nonprimed Raji cells. With the stimulation of SEE-
primed Raji cells, GFP-fused wt, S552A, or S555A ver-
sion of CARMA1 were translocated to the contact sites
between Jurkat and Raji cells and colocalized with
CTx-ALEXA-labeled lipid rafts (Figure 6C). In contrast,
the recruitment of GFP-CARMA1(L808P), which is defec-
tive for the localization to cytoplasm membrane (Wang
et al., 2004), to the lipid raft in the contact site between
Jurkat and Raji cells was defective (Figure 6C, bottom).
This result indicates that the mutation of Ser552 or
Ser555 in CARMA1 does not affect the recruitment of
CARMA1 to the immunological synapse. Together, these
data demonstrate that the failure of CARMA1(S552A) and
CARMA1(S555A) to mediate TCR-induced NF-kB acti-
vation is because these CARMA1 mutants are defective
in recruiting downstream signaling components into the
immunological synapse and fail to fully induce IKK acti-
vation.
Discussion
CARMA1 is a scaffold molecule, which is required for an-
tigen receptor-induced NF-kB activation (Egawa et al.,
2003; Hara et al., 2003; Jun et al., 2003; Newton and
Dixit, 2003; Wang et al., 2002). However, how CARMA1
mediates antigen receptor-induced NF-kB activation is
not clear (Lin and Wang, 2004). In this study, we have
demonstrated that CARMA1 is constitutively phosphor-
ylated, and PMA-CD28 costimulation further enhances
the phosphorylation. Since previous studies indicate
that PKCq functions upstream of CARMA1, we have ex-
amined whether PKCq can phosphorylate CARMA1 di-
rectly or indirectly. Our results suggest that PKCq can di-rectly phosphorylate CARMA1 on Ser552 in the Linker
region between the coiled-coil and PDZ domains of
CARMA1. Importantly, the mutation of CARMA1 on
Ser552 disrupts TCR-induced NF-kB activation in T
cells. Therefore, our studies provide genetic evidence
that PKC-mediated phosphorylation of CARMA1 plays
a critical role in the TCR signaling pathway.
The Linker region of CARMA1 is highly enriched in
Ser or Thr residues. However, the single mutation with
Ser505, Ser508, Ser549, Ser551, or Ser637 and multiple
mutations with Ser470/Ser471/Ser473 or Ser611/Ser612/
Ser613/Ser614/Ser615 have no effects on CARMA1’s
function (Table 1), indicating that the phosphorylation
sites in CARMA1 are highly specific. Interestingly, al-
though the Linker regions of CARMA1 and CARMA3
share only about 25% of homology, expression of
CARMA3 can rescue the defect in CARMA1-deficient
cells. Moreover, the point mutation of Ser520 of
CARMA3, which is homologous to Ser552 or Ser555 in
CARMA1 (Figure 3B), completely abolishes CARMA3’s
ability to rescue the NF-kB defect in CARMA1-deficient
cells (Figure S1). Together, these results indicate that
Ser552 and Ser555 of CARMA1 play a critical role in
TCR-induced NF-kB activation. Of note, unlike the sta-
ble expression stage (Figure 4B), the single mutation
of Ser552 only partially reduces its activity in the tran-
sient transfection assay (Figure 4A). This could be due
to the nearby Ser residues, 551 and 549, that can some-
what compensate the defect, when CARMA1(S552A)
is transiently overexpressed. Consistent with this hy-
pothesis, combined mutations of Ser549, Ser551, and
Ser552 completely abolish the function of CARMA1
(Table 1).
Ser552, Ser555, and Ser645 in CARMA1 are predicted
to be potential PKC phosphorylation sites (http://scansite.
mit.edu). Consistent with this prediction, mutations of
Ser552, Ser555, and Ser645 to Ala impair CARMA1-
mediated NF-kB activation in TCR pathway (Figure 4
and Table 1). However, unlike the S552A mutant that
was significantly defective in PKCq-induced phosphory-
lation, mutations on Ser555 and Ser645 had little effect
on PKCq-induced phosphorylation in vitro (Figure 5).
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(A and B) JPM50.6 cells (23 107), which were stably reconstituted with wild-type or mutant versions of CARMA1, were stimulated with or without
anti-CD3 and anti-CD28 antibodies. The cells were then lysed with 1% Triton X-100 buffer. Some lysates were examined by Western blots with
anti-Myc, anti-p-ERK, or anti-ERK antibodies (A). Some lysates were subjected to sucrose density gradient centrifugation to isolate lipid rafts.
Equal volume of representative fractions was collected. The lipid raft and detergent-soluble fractions were combined and then separated by
SDS-PAGE and examined by Western blots with antibodies specific for Bcl10, NEMO, and Lck (B).
(C) Jurkat T cells were transfected with GFP-fused wt, L808P, S552A, or S555A version of CARMA1. The transfected Jurkat cells were incubated
with ALEXA594-conjugated CTx (red) and then stimulated with SEE-primed or nonprimed Raji cells. The subcellular localization of CARMA1
(green) and lipid rafts (red) was visualized by a confocal fluorescent microscope. Asterisks indicate Raji cells.These results suggest that Ser552 is one of the func-
tional phosphorylation sites for PKCq, whereas both
Ser555 and Ser645 may play an important structural
role for CARMA1’s function. Since Ser555 is near
Ser552, it is possible that mutations of Ser555 may com-
pletely alter the secondary structure of nearby Ser552 or
the structure of the Linker region. However, it remains to
be determined why S645A mutation also leads to a par-
tial defect in NF-kB activation (Table 1), since this resi-
due appears to not be a main phosphorylation site for
PKCq (Figure 5).
Although the majority of Ser552 we identified in the
mass spectra analysis was nonphosphorylated (data
not shown), we were able to detect a small amount of
phosphorylated Ser552 in CARMA1. Nevertheless, this
small amount of phosphorylation on Ser552 could be
functionally significant, since not all of CARMA1 is re-
cruited to the lipid raft, and this amount of inducible
phosphorylation may be sufficient to activate CARMA1-
dependent signaling events. Interestingly, we also found
a small amount of phosphorylated Ser565 in the MS
analysis. Although Ser565 in CARMA1 does not fall
into the putative PKC consensus site, the mutation of
Ser565 also leads to the functional defect of CARMA1(Table 1). The role of Ser565 of CARMA1 will be further
investigated in the future. In addition, PKCq can phos-
phorylate other sites in CARMA1 besides Ser552, when
they are overexpressed together with CARMA1 (Fig-
ure S3). Therefore, it remains to be determined whether
other phosphorylation sites are also functionally impor-
tant.
The role of this PKCq-induced phosphorylation on
CARMA1 is most likely to induce a conformational
change in such a way that the downstream signaling
component Bcl10 can associate with CARMA1. The
phosphorylation region does not appear to be the bind-
ing site of Bcl10, since earlier studies have suggested
that Bcl10 associates with the N-terminal CARD domain
of CARMA1. One possible role of this phosphorylation of
CARMA1 is that the Linker region is required for binding
of an unknown inhibitory protein that may block the ac-
cessibility of the CARD domain of CARMA1 from Bcl10.
Once the Linker region is phosphorylated, this inhibitory
protein may dissociate from CARMA1. However, this hy-
pothesis is not consistent with our data that mutations
of Ser552 or Ser555 to Asp cannot mimic the phos-
phorylation, which would be constitutive mutants of
CARMA1, since introducing the negative charged side
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phorylation of CARMA1 and NF-kB Activation
CD3-CD28 costimulation activates various
proximal signaling components that lead
to activation of PKCq, which, in turn, phos-
phorylates CARMA1. The phosphorylated
CARMA1 recruits the Bcl10-MALT1 complex
that further activates TRAF6. The activated
Bcl10-MALT1 complex and TRAF6 induce
the ubiquitination and activation of IKK com-
plex, leading to activation of NF-kB.chain on residues 552 or 555 may mimic the phosphor-
ylation of these Ser residues and disrupt the interaction
between the Linker region of CARMA1 and an inhibitory
protein. However, we found that these mutants were
also partially or completely defective for TCR-mediated
NF-kB activation in CARMA1-deficient T cells (Fig-
ure S5). Therefore, the more possible mechanism is
that the CARD domain of CARMA1 is buried in the un-
stimulated stage. Following the stimulation, the Linker
region of CARMA1 is phosphorylated by PKCq, which in-
duces a conformational change, and exposes the CARD
domain for binding of Bcl10. This hypothesis will be
tested in the future studies.
The defect of mutations on Ser552 and Ser555 is due
neither to the loss of ability to bind to Bcl10, since the
overexpression of these mutants can effectively activate
NF-kB (Figure S6) and bind to the endogenous Bcl10
(data no shown) in HEK293 cells, nor to the defect of
translocation to the immunological synapse (Figure 6C).
Together, these results further support our conclusion
that mutations on Ser552 and Ser555 are likely disrupt-
ing the signals from upstream components, such as
PKCq, to activate CARMA1 after TCR stimulation.
Although our results suggest that PKCq phosphory-
lates CARMA1, we cannot rule out the possibility that
an undefined kinase may also phosphorylate CARMA1.
Due to technical difficulties, we cannot obtain recombi-
nant full-length CARMA1 protein. As an alternative, we
immunoprecipitated the overexpressed CARMA1 from
transfected HEK293 cells and used the immunoprecipi-
tated CARMA1 as substrates for PKCq in the in vitro ki-
nase assays. Therefore, there is a possibility that PKCq
actually activates an undefined kinase that is associated
with the immunoprecipitated CARMA1 and phosphory-
lates CARMA1 in the in vitro kinase assay (Figure 2). In
addition, when we used other isoforms (a, b, d, 3) of re-
combinant PKC, we also found that all of them can phos-
phorylate the Linker region of CARMA1 (data not
shown). Therefore, we believe that the specificity of
CARMA1 phosphorylation is also regulated through
the intracellular localization of individual PKC, since it
has been shown that PKCq is the only isoform of PKCs
translocated into the immunological synapse after thestimulation by APC (Monks et al., 1997). In B cells, it
has been shown that PKCb is the key isoform of PKCs
involved in BCR-induced NF-kB activation (Saijo et al.,
2002; Su et al., 2002). Therefore, it is likely that PKCb
will also phosphorylate CARMA1 in the similar region
of CARMA1 in B cells and lead to activation of NF-kB.
In summary, our results provide the genetic evidence
that TCR signaling pathway leads to activation of PKCq
that phosphorylates CARMA1 in its Linker region. The
phosphorylationofCARMA1mayinduceaconformational
change, which exposes the binding site of CARMA1 for
downstream signaling components such as Bcl10 and
IKK and leads to activation of NF-kB (Figure 7). Future
studies to determine the mechanism by which the phos-
phorylated CARMA1 recruits downstream signaling com-
ponents will provide molecular insight for designing ther-
apeutic agents for cancer and autoimmune diseases.
Experimental Procedures
Expression Plasmids, Recombinant Proteins, Antibodies,
and Cell Lines
Expression plasmids encoding Bcl10, MALT1, PKCq, IKKb, and
CARMA3 were described previously. CARMA1 was cloned into
a mammalian expression vector, pCMV-Tag2 (STRATAGENE), at
BamHI and EcoRI sites. All mutations of CARMA1 and CARMA3
were generated by Quick Change mutagenesis (STRATAGENE).
Plasmids encoding green fluorescent protein (GFP) fused to the
wild-type, S552A, S555A, or L808P point mutant of CARMA1 were
subcloned into pEGFP-C1 vector (Clontech). Plasmids encoding
GST fused to the wild-type or mutant versions of CARMA1(432-
671), which encodes 240 residue fragment with individual Ser resi-
dues converted into Ala, were generated by PCR and subcloned
into pGEX4-T1 vector. The resulting expression vectors were trans-
formed to E. coli strain BL21. The recombinant GST fusion proteins
were purified from the bacterial lysates with GST-agarose beads.
Recombinant PKCs were purchased from Stratagene. Various anti-
bodies were purchased from BD Biotechnology (PKCq, CD3), Santa
Cruz Biotechnology (Bcl10, NEMO, IKKb, ERK, Myc, Lck, and Tubu-
lin), Caltag Biotechnology (CD28), and Cell Signaling (phospho-IkBa,
phospho-IKKb, phospho-ERK1/2, phospho-Ser-PKC substrates).
CARMA1 antibodies (Wang et al., 2002) were raised by immunizing
rabbits with a 15 amino acid peptide (RYKEDAPHRSTVEED), which
responds to residues 569–583 of CARMA1, kindly provided by
Dr. John Bertin (Millennium Pharmaceuticals), and anti-CARMA1
N-term antibodies were provided by Dr. Margot Thome (University
of Lausanne).
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ously (Wang et al., 2002). JPM50.6 cells expressing mutants of
CARMA1 were generated by the reconstitution of JPM50.6 cells
with lentiviral vectors encoding wt or mutants of CARMA1.
32P-Labeling of Bcl10 and CARMA1 In Vivo
Jurkat T cells (1 3 107/ml) or JPM50.6 cells (1 3 107/ml) were cul-
tured in phospho-free media for 60 min, and then 32P-orthrophos-
phate (0.5 mCi/ml) was added into the media and cultured for
15 min. The labeled cells (1 3 107/sample) were stimulated with or
without 50 ng/ml PMA plus 1 mg/ml anti-CD28 antibodies for various
times. Endogenous Bcl10 or CARMA1 proteins were immunopre-
cipitated with anti-Bcl10 or CARMA1 antibody-conjugated agarose
beads. The immunoprecipitates were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and trans-
ferred to nylon membranes for autoradiography and immunoblotting
analyses. For detecting PKCq-induced phosphorylation of CARMA1
in vivo, the expression vector for Flag-tagged CARMA1 was cotrans-
fected with or without expression vectors of wt or a constitutively
active version (AE) of PKCq into HEK293 cells in a 6-well plate.
16 hr after the transfection, cells were cultured in phospho-free
media for 60 min, and then 32P-orthrophosphate (0.1 mCi/ml) was
added into the media and cultured for 60 min. The labeled cells
were lysed, and the cell lysates were immunoprecipitated with
anti-Flag antibodies-conjugated agarose beads. The immunopreci-
pitated samples were then subjected to SDS-PAGE and examined
by autoradiography and immunoblots.
In Vitro Kinase Assay
For detection of PKCq-induced phosphorylation of CARMA1, Flag-
tagged CARMA1, Bcl10, and MALT1 proteins were immunoprecipi-
tated from transfected HEK293 cells by Flag antibodies-conjugated
agarose beads and then eluted with Flag peptides. The eluted Flag-
CARMA1, Bcl10, and MALT1 were mixed with kinase buffer (10 mM
HEPES [pH 7.4], 1 mM MnCl2, 5 mM MgCl2, 12.5 mM Glycero-2-
Phosphate, 0.05 mM Na3VO4, 2 mM NaF, 0.5 mM DTT, 10 mM ATP,
plus 5 mCi [g-32P]ATP) in the presence or absence of 10 ng recombi-
nant His-tagged PKCq (Invitrogen) with or without 20 ng of PMA.
Samples were incubated for 30 min at 30ºC. For GST-fusion protein
kinase assay, substrate GST fusion peptides from wt and mutated
CARMA1 were expressed and purified by B-PER Bacterial Protein
Extraction Reagent (PIERCE). After dialysis, 2 mg of purified GST fu-
sion peptide was used and 10 ng of recombinant His-tagged PKCq
was added into kinase buffer with or without 20 ng of PMA. Samples
were incubated for 30 min at 30ºC. The kinase reactions were
stopped by adding 20 ml of 2X SDS Loading buffer. Samples were
then subjected to SDS-PAGE and autoradiography.
Luciferase Reporter Assay
JPM50.6 cells (8 3 106 in 0.4 ml serum-free RPMI1640 media) were
electroporated with 5 mg of NF-kB-dependent luciferase (firefly) re-
porter plasmid and 100 ng of EF1a promoter-dependent Renilla lu-
ciferase reporter together with 10 mg of expression vectors for vari-
ous CARMA1 derivatives, CARMA2, CARMA3, or vector controls at
the power setting of 250 V and 960 mF. The transfected cells were
cultured in 8 ml RPMI1640 with 10% FCS for 16 hr. The cells were
then stimulated with or without anti-CD3 (1 mg/ml) and anti-CD28
(1 mg/ml) antibodies or PMA (10 ng/ml) plus anti-CD28 (1 mg/ml) anti-
bodies for 6 hr. The cells were lysed. Luciferase activities in the cell
lysates were measured by dual-luciferase kit (Promega).
Cell Stimulation and Lipid Raft Isolation
Costimulation of cells was performed by addition of anti-CD3
(10 mg/ml) and anti-CD-28 (5 mg/ml), together with 15 mg/ml of anti-
mouse immunoglobulin G (Signal Transduction Lab., San Diego,
CA). Lipid rafts were separated by sucrose density gradient centrifu-
gation as described previously (Bi et al., 2001). In brief, cells (23 107)
were lysed in 1 ml of MNE buffer (25 mM MES [pH 6.5], 150 mM NaCl,
5 mM EDTA, 30 mM sodium pyrophosphate, 1 mM sodium ortho-
vanadate, and a protease inhibitor cocktail) with 1% Triton X-100
on ice for 20 min. The lysates were homogenized with 20 strokes
of a loose-fitting Dounce homogenizer and centrifuged at 1000 3 g
for 10 min at 4ºC. The supernatants were transferred to a Beckman
ultracentrifuge tube and mixed with 1 ml of 80% sucrose in MNEbuffer. Next, 2 ml of 30% sucrose followed by 1 ml of 5% sucrose
in MNE buffer were overlaid. Samples were centrifuged in a
SW50Ti rotor at 200,000 3 g for 20 hr at 4ºC and fractionated into
12 fractions from the top of the gradient. Fractions 2–5 or fractions
7–11 were combined and are referred to as lipid raft (Triton-insoluble
glycolipid-enriched membranes) or Triton-soluble fractions, respec-
tively. Proteins from collected fractions were precipitated with tri-
chloroacetic acid before separation by 10% SDS-PAGE.
Detection of CARMA1 in Immunological Synapses
Detection of immunological synapse formation was performed as
described previously (Wang et al., 2004). Jurkat cells were trans-
fected with 20 mg of pEGFP-CARMA1 wt, S552A, S555A, or L808P
with a Gene Pulser (Bio-Rad) at 250V (950mF). 24 hr after transfec-
tion, the transfected Jurkat cells were stained with ALEXA594-
conjugated cholera toxin B (CTxB) (8 mg/ml [Sigma]) at 4ºC for
20 min. Cells were then washed and resuspended in serum-free
RPMI 1640 at 106 cells per ml. Raji cells were incubated in serum-
free RPMI 1640 (Hyclone) with or without 2 mg of Staphylococcus
exotoxin E (SEE Toxin Technology, Inc., Sarasota, FL) per ml at
37ºC for 1.5 hr. Raji cells were then washed and resuspended in
serum-free RPMI 1640 at 106 cells per ml. A total of 0.5 ml of Raji cells
was mixed with an equal volume of Jurkat cells, and the cells were
mixed thoroughly by pipetting and then pelleted at 500 rpm for
5 min at room temperature. A total of 0.5 ml of supernatant was re-
moved, and pellets were incubated for 30 min at 37ºC. Tubes were
resuspended by vortexing. Cells were fixed in 4% paraformaldehyde
and attached to poly-L-lysine-coated microscope slides by cyto-
spin. Fluorescence was detected by OLYMPUS FLUOVIEW FV300
confocal laser scanning biological microscope.
Peptide Mapping by Mass Spectra
JPM50.6 cells expressing Flag-tagged CARMA1(WT) were stimu-
lated with or without 50 ng/ml PMA plus 1 mg/ml anti-CD28 antibod-
ies for 5 min. Cell lysates were immunoprecipitated with anti-Flag
antibody-conjugated beads and subjected to SDS-PAGE, followed
by silver staining. CARMA1 proteins were cut out from the gel and
digested in gel with trypsin. After Zip-Tip cleanup, the peptides
were analyzed with LC-MS/MS (FINNIGAN LTQ ESI-ion trap system,
Thermo Electron). The MS/MS spectra will be analyzed by the
MS/MS ion searching program of MASCOT (Matrix Science; avail-
able on the World Wide Web at http://www.matrixscience.com)
and Bioworks Browser software (version 3.0) (Thermo Electron) to
assign individual mass signals, determine amino acid sequences,
and define phosphorylated amino acids.
Supplemental Data
Supplemental Data include six figures and one table and can be
found with this article online at http://www.immunity.com/cgi/
content/full/23/6/575/DC1/.
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